What question did this study set out to answer?

Evaluate the efficacy and safety of SPEDOX-6, a novel doxorubicin formulation, for treating soft tissue sarcomas.

April 5, 2026

Abstract 3903: SPEDOX-6: First-in-human Phase IB/IIA trial on soft tissue sarcomas.

Key Points

Evaluate the efficacy and safety of SPEDOX-6, a novel doxorubicin formulation, for treating soft tissue sarcomas.
Conducted Phase IB/IIA trial in human subjects
Utilized a patented single protein encapsulation platform
Compared pharmacokinetic profiles and tumor efficacy in mouse and rat models
SPEDOX-6 shows significantly lower cardiotoxicity than doxorubicin in animal models
Efficacy against tumors inversely correlates with neonatal Fc receptor levels
Initial human trials indicate potential for high-dose administration with reduced side effects

Abstract

Abstract Purpose: Soft tissue sarcomas (STSs) are extremely aggressive 4-folds DOX) can be used for treating patients without cardiotoxicity, which will save lots of lives. Citation Format: C. J. Yu, Kinsley leslie Wang, Wang, Mengmeng Liu, Faqing Huang, Warren A. Chow, Xiaojiang Cui. SPEDOX-6: First-in-human Phase IB/IIA trial on soft tissue sarcomas abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3903.

Abstract 3903: SPEDOX-6: First-in-human Phase IB/IIA trial on soft tissue sarcomas.

Key Points

Abstract

Cite This Study